Transcatheter aortic valve replacement
Minimally invasive procedure to replace a narrowed aortic valve
Transcatheter aortic valve replacement (TAVR), also known as transcatheter aortic valve implantation (TAVI), is a minimally invasive procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis). TAVR is an option for patients who are considered to be at intermediate or high risk for open-heart surgery.
Procedure[edit | edit source]
TAVR involves inserting a catheter through the femoral artery in the groin or through a small incision in the chest. The catheter is guided to the heart, where a replacement valve is deployed. The new valve is typically made from animal tissue and is mounted on a balloon-expandable or self-expanding stent. Once in place, the new valve takes over the function of regulating blood flow from the heart to the aorta.
Indications[edit | edit source]
TAVR is primarily indicated for patients with severe aortic stenosis who are at increased risk for complications from traditional open-heart surgery. It is also considered for patients who are not candidates for surgery due to other medical conditions. The decision to perform TAVR is based on a comprehensive evaluation by a heart team, including cardiologists and cardiac surgeons.
Benefits and Risks[edit | edit source]
The benefits of TAVR include a shorter recovery time compared to open-heart surgery, reduced hospital stay, and improved quality of life. However, TAVR carries risks such as bleeding, vascular complications, stroke, and the need for a permanent pacemaker. Long-term durability of the valve is also a consideration.
History[edit | edit source]
The first successful TAVR procedure was performed in 2002 by French cardiologist Alain Cribier. Since then, the procedure has evolved significantly, with improvements in valve design and delivery systems. TAVR has become a widely accepted treatment for aortic stenosis, with numerous clinical trials demonstrating its safety and efficacy.
Related pages[edit | edit source]
References[edit | edit source]
External links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
